Douglas Flora: MRD in Solid Tumors – GI Updates from ASCO 2025
Douglas Flora, President-Elect Association of Cancer Care Centers at Association of Cancer Care Centers, shared AI in Precision Oncology’s post on LinkedIn:
“The second of three in this MRD series from the editors of AI in Precision Oncology, reviewing the emerging data on MRD in solid tumors.
This time, we learn from the esteemed Dr. Midhun Malla, giving us pearls everywhere – essentially a webinar version of “How I Treat”. We cover GI data this time, including some important updates from ASCO ‘25.
Please consider joining us for this informative discussion, generously supported this time by our friends at Natera.”
Quoting AI in Precision Oncology’s post:
“DON’T MISS OUT! Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing
Wednesday, September 10th, 2025
4:00 pm ET, 1:00 pm PT, 22:00 CET
In this panel, our industry experts will discuss the impactful role of circulating tumor DNA (ctDNA) testing for MRD assessment in GI cancer management. Key learnings for this webinar:
- The role of MRD testing in risk stratification, refining treatment pathways, and augmenting personalized oncology care
- Latest evidence supporting MRD as a predictive biomarker in GI malignancies, including its application in the neoadjuvant setting, adjuvant treatment decision-making, early relapse detection, ongoing surveillance, and informing metastatic directed therapy (MDT)
- How to integrate MRD testing into your practice to enable more precise, personalized, and timely treatment decisions
Register now to join us for this free webinar sponsored by Natera.”
More from Douglas Flora.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023